Carregant...
Impact of the US Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture
The U.S. FDA issued several announcements related to potential risk of bisphosphonates including osteonecrosis of the jaw (2005), atrial fibrillation (2007) and atypical femur fracture (2010). We aimed to evaluate the impact of three FDA drug safety announcements on the use of bisphosphonates in pat...
Guardat en:
| Publicat a: | J Bone Miner Res |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5040596/ https://ncbi.nlm.nih.gov/pubmed/26969902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.2832 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|